Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection (OTL38) for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer

NCT03180307 is registered in ClinicalTrials.gov with On Target Laboratories, LLC as lead sponsor.

NCT NCT03180307
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03180307 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection (OTL38) for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer
Lead sponsor
On Target Laboratories, LLC
Phase
Phase 3
Overall status
Completed
Start date
January 26, 2018
Completion date
October 16, 2020
Enrollment
140 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer